Pipeline dossier

NIH & clinical-trial pipeline signals for ASTRAZENECA PLC (AZN)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for AZN, mapped to public ticker AZN (CIK 0000901832). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingAZN55% conf

ASTRAZENECA PLC (AZN) — PHASE1 primary completion in ~60 days

Upstream (observed)
Clinical trial status (PHASE1) — A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingAZN35% conf

ASTRAZENECA PLC (AZN) — PHASE1 protocol updated 2 days ago

Upstream (observed)
Clinical trial status (PHASE1) — A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

JSON API for this entity →